LONDON (ShareCast) - (ShareCast News) - Life science company SkinBioTherapeutics has passed third party cellular toxicity tests for its 'SkinBiotix' technology, it announced on Tuesday, which the board said confirmed previous in-house observations on its safety and applicability.
The AIM-traded firm said the cytotoxicity studies were conducted by the contract research organisation Charles River in accordance with the OECD Principles of Good Laboratory Practice.

The objective of the toxicity tests was to determine if there were "any adverse biological reactions" from mammalian cell cultures following the use of SkinBiotix technology.

"Following incubation for 24 hours, no cytotoxicity was observed ... [either] malformation of cells or cell degeneration," SkinBioTherapeutics said in its statement.

"The data confirm SkinBioTherapeutics' in-house observations on how mammalian skin cells and fibroblasts respond to being exposed to SkinBiotix.

"This further supports the principle of SkinBiotix's suitability for use in skin care applications."

The company said two further tests, phototoxicity and in vitro ocular toxicity, were scheduled, with results set to be reported when the data is received.

"The result from the cytotoxicity testing by Charles River is essential external validation of our SkinBiotix platform," said CEO Dr Catherine O'Neill.

"This was one of the key milestones to pass and was highlighted as such at the IPO.

"Its passing marks a critical step in our progression and the transitioning of the technology into human validation studies."

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE